We are live on ! Find out more
SLDB icon

Solid Biosciences
SLDB

39 hedge funds and large institutions have $74.8M invested in Solid Biosciences in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

11% more funds holding

Funds holding: 35 → 39 (+4)

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

12% less capital invested

Capital invested by funds: $85.3M → $74.8M (-$10.6M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $7K

122.44% less ownership

Funds ownership: 203.04% → 80.6% (-122%)

Holders
39
Holders Change
+4
Holders Change %
+11.43%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
8
Reduced
9
Closed
6
Calls
–
Puts
$7K
Net Calls
-$7K
Net Calls Change
-$218K

Top Buyers

Rank Fund Capital Flow
1
FC
Finepoint Capital
Massachusetts
+$1.62M
2
PVI
Pura Vida Investments
New York
+$1.35M
3
GPP
Great Point Partners
Connecticut
+$1.26M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$640K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$112K

Top Sellers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
-$1.84M
2
CCM
CAAS Capital Management
New York
-$235K
3
Renaissance Technologies
Renaissance Technologies
New York
-$78.1K
4
Millennium Management
Millennium Management
New York
-$69K
5
OWP
Old Well Partners
North Carolina
-$58.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$20.9K -$120 -20 -0.5%
Bank of America
27
Bank of America
North Carolina
$11K -$2.39K -397 -15%
Lazard Asset Management
28
Lazard Asset Management
New York
$9K +$12.6K +2,089 New
MCM
29
Manchester Capital Management
Vermont
$4.74K – – –
Fidelity Investments
30
Fidelity Investments
Massachusetts
$1.42K +$1.8K +300 New
Group One Trading
31
Group One Trading
Illinois
$1.3K -$78 -13 -5%
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$1K -$421 -70 -22%
JP Morgan Chase
33
JP Morgan Chase
New York
$1K – – –
UBS Group
34
UBS Group
Switzerland
$787 – – –
Osaic Holdings
35
Osaic Holdings
Arizona
$748 +$769 +128 +427%
First Manhattan
36
First Manhattan
New York
$630 – – –
Wells Fargo
37
Wells Fargo
California
$583 +$174 +29 +31%
BAAM
38
Baker Avenue Asset Management
California
$313 +$397 +66 New
PA
39
Parallel Advisors
California
$28 – – –
KPF
40
K2 Principal Fund
Ontario, Canada
– -$1.84M -342,271 Closed
Millennium Management
41
Millennium Management
New York
– -$69K -12,846 Closed
OWP
42
Old Well Partners
North Carolina
– -$58.1K -10,800 Closed
Acadian Asset Management
43
Acadian Asset Management
Massachusetts
– -$50K -9,507 Closed
BAM
44
Belpointe Asset Management
Nevada
– -$7.35K -1,367 Closed
IRC
45
Investors Research Corp
Georgia
– -$70 -13 Closed
1
2

SLDB Hedge Fund Activity: Q1 2023 in Review

39 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q1 2023, worth a combined $74.8M — down 12% from $85.3M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new SLDB positions and 6 closed out — a net gain of 4 holders — while 8 added to existing stakes and 9 trimmed.

The largest buyer was Finepoint Capital, adding an estimated $1.62M. The largest seller was K2 Principal Fund, exiting entirely with an estimated $1.84M sold.

  • 39 institutional investors held Solid Biosciences (SLDB) as of Q1 2023, up from 35 in Q4 2022.
  • Funds reported $74.8M of Solid Biosciences stock for Q1 2023, down 12% quarter-over-quarter.
  • 10 funds opened new Solid Biosciences positions in Q1 2023 and 6 closed out, a net change of +4 holders.
  • The largest Solid Biosciences buyer in Q1 2023 was Finepoint Capital, an estimated $1.62M added.
  • The largest Solid Biosciences seller in Q1 2023 was K2 Principal Fund, an estimated $1.84M sold.

Based on aggregated 13F filings for Q1 2023.